Resmed Inc. Stock
Resmed Inc. Stock
Resmed Inc. gained 0.360% compared to yesterday.
Resmed Inc. is currently one of the favorites of our community with 20 Buy predictions and no Sell predictions.
As a result the target price of 256 € shows a positive potential of 30.75% compared to the current price of 195.8 € for Resmed Inc..
Pros and Cons of Resmed Inc. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | 0.360% | 0.746% | -3.117% | 3.900% | -6.091% | -4.534% | 13.903% |
| Veeva Systems A | 4.260% | -10.673% | -13.925% | -29.891% | -29.634% | -17.685% | -40.455% |
| Thermo Fisher Scientific Inc. | 3.000% | 2.677% | 7.208% | 13.246% | -11.514% | -18.292% | 7.842% |
| Intuitive Surgical Inc | 1.500% | -0.472% | -5.749% | -10.299% | -20.229% | 61.674% | 76.136% |
Comments
ResMed (RMD) was given a new $255.00 price target by Evercore Inc. They now have an "outperform" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (RMD) had its price target lowered by Citigroup Inc. from $345.00 to $340.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
